2024
Racial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
2020
Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study.
Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. Journal Of The National Comprehensive Cancer Network 2020, 18: 729-736. PMID: 32502978, DOI: 10.6004/jnccn.2020.7529.Peer-Reviewed Original ResearchConceptsHospital referral regionsCurative treatmentHepatocellular carcinomaIncidence of HCCCox proportional hazards modelSEER-Medicare studyPercutaneous ethanol injectionHepatitis B virusProportional hazards modelMore comorbiditiesSurgical resectionSurvival benefitTreatment patternsSEER-MedicareB virusRadiofrequency ablationEthanol injectionTreatment utilizationReferral regionsBetter survivalLower riskHazards modelPatientsSurvivalTreatment
2014
Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival
Wang SY, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP, Chen J. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Research And Treatment 2014, 146: 411-419. PMID: 24951268, DOI: 10.1007/s10549-014-3029-0.Peer-Reviewed Original ResearchConceptsCardiovascular eventsEarly discontinuationTrastuzumab treatmentCause mortalityTrastuzumab therapyTrastuzumab discontinuationBreast cancerCox proportional hazards modelContinuous trastuzumab treatmentAdverse cardiovascular eventsPopulation-based cohortFemale Medicare beneficiariesHigher mortality riskProportional hazards modelNon-significant increaseCardiovascular complicationsOlder patientsOverall survivalHeart failureAtrial fibrillationDiscontinuationMortality riskOlder womenMedicare beneficiariesHazards model